Adaptive Biotechnologies Corp's stock surged 6.25% in after-hours trading following the release of its fourth-quarter 2025 financial results that significantly exceeded analyst expectations.

The biotechnology company reported Q4 revenue of $71.68 million, representing a 51% year-over-year increase and beating the consensus estimate of $59.39 million. More notably, Adaptive Biotechnologies achieved adjusted EBITDA of $4.10 million, dramatically outperforming analyst expectations of a $7.45 million loss and marking a positive turnaround for the company's financial performance.

The company's MRD (minimal residual disease) business showed particularly strong results, with revenue growing 54% in Q4 and contributing 86% of total revenue. Adaptive Biotechnologies also provided optimistic guidance for 2026, expecting MRD revenue between $255 million and $265 million. Additional positive developments included expanded Medicare coverage for the clonoSEQ test in mantle cell lymphoma and new data licensing agreements with Pfizer, contributing to investor optimism about the company's growth trajectory.